BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced new preclinical data from its lead program KLN-1010, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. KLN-1010, a novel, in vivo CAR-T cell therapy candidate for the treatment of multiple myeloma, which leverages the company’s in vivo Gene Placement System (iGPS®) technology, demonstrated that it is safe and effective in preclinical animal models..

波士顿--（商业新闻短讯）--Kelonia Therapeutics是一家革新体内基因传递的生物技术公司，今天宣布了其领先项目KLN-1010的新临床前数据，该数据将在2024年美国癌症研究协会（AACR）年会上在加利福尼亚州圣地亚哥举行。KLN-1010是一种用于治疗多发性骨髓瘤的新型体内CAR-T细胞治疗候选药物，它利用了该公司的体内基因定位系统（iGPS®）技术，证明它在临床前动物模型中是安全有效的。。

“These data reinforce the best-in-class potential of our in vivo CAR-T cell therapies,” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia. “By eliminating the need for ex vivo manufacturing and toxic lymphodepleting chemotherapy, we believe our iGPS technology will remove barriers that currently prevent patients from accessing transformative genetic medicines.

Kelonia首席执行官兼创始人凯文·弗里德曼博士说：“这些数据强化了我们体内CAR-T细胞疗法的最佳潜力。”。“通过消除离体制造和毒性淋巴清除化疗的需要，我们相信我们的iGPS技术将消除目前阻止患者获得转化基因药物的障碍。

We are excited by the preclinical profile of KLN-1010, and are looking forward to advancing this program towards the clinic in the near future.”.

我们对KLN-1010的临床前概况感到兴奋，并期待着在不久的将来将该计划推向临床。”。

Diverse T cell lineages, including memory and effector CD4 and CD8 T cells were modified in vivo by KLN-1010 to express a fully human anti-BCMA CAR, without detectable transduction of multiple myeloma tumor cells. A single intravenous injection of KLN-1010 displayed potent anti-tumor efficacy and caused complete tumor regression at multiple dose levels in several preclinical animal models.

KLN-1010在体内修饰了多种T细胞谱系，包括记忆和效应CD4和CD8 T细胞，以表达完全人抗BCMA CAR，而没有可检测到的多发性骨髓瘤肿瘤细胞转导。单次静脉注射KLN-1010显示出有效的抗肿瘤功效，并在几种临床前动物模型中以多剂量水平引起肿瘤完全消退。

In other studies, treatment of non-human primates with an iGPS particle expressing an anti-CD20 CAR resulted in potent CAR-T cell activity lasting several months without the need for additional treatments or conditioning chemotherapy..

在其他研究中，用表达抗CD20 CAR的iGPS颗粒治疗非人灵长类动物导致有效的CAR-T细胞活性持续数月，而不需要额外的治疗或调理化疗。。

Details for the poster presentation are as follows:

海报展示详情如下：

Title: T cell-specific in vivo transduction with preclinical candidate KLN-1010 generates BCMA directed CAR T cells with potent anti-multiple myeloma activity

标题：临床前候选KLN-1010的T细胞特异性体内转导产生具有有效抗多发性骨髓瘤活性的BCMA定向CAR T细胞

Poster Session: Adoptive Cell Therapies 2: CAR-T Cells

海报环节：过继细胞疗法2：CAR-T细胞

Date and Time: April 7, 2024 at 1:30-5:00 pm PT

日期和时间：2024年4月7日下午1:30-5:00

Location: Section 2

位置：第2节

Poster Number: 16

海报编号：16

About Kelonia Therapeutics

关于Kelonia Therapeutics

Kelonia is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS®). The company’s elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modifications to improve in vivo gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery.

Kelonia利用其体内基因定位系统（iGPS®）开创了新一波遗传药物的先河。该公司优雅、尖端的体内基因传递技术使用了一种先进的慢病毒载体颗粒，该载体颗粒带有包膜修饰，以提高体内基因转移效率和向性分子，从而促进组织特异性传递。

Initially focused on developing transformational in vivo CAR-T therapies for hematologic cancers, Kelonia is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. Learn more about Kelonia at https://www.keloniatx.com/ and follow us on LinkedIn and Twitter..

Kelonia最初专注于开发针对血液系统癌症的转化性体内CAR-T疗法，目前正在为一系列疾病建立基因药物管道，其大胆目标是让每一位需要的患者在何时何地都可以获得基因药物。了解有关科隆尼亚的更多信息，请访问https://www.keloniatx.com/并在LinkedIn和Twitter上关注我们。。